Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $6.00 for the company and are forecasting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned HTG Molecular Diagnostics an industry rank of 179 out of 265 based on the ratings given to related companies.

Several research analysts have recently weighed in on the stock. HC Wainwright set a $6.00 price objective on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Wednesday, November 15th. Finally, ValuEngine lowered shares of HTG Molecular Diagnostics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 10th.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA lifted its stake in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 416,608 shares of the medical research company’s stock after acquiring an additional 345,798 shares during the period. Granahan Investment Management Inc. MA owned 3.33% of HTG Molecular Diagnostics worth $708,000 as of its most recent SEC filing. Institutional investors and hedge funds own 15.15% of the company’s stock.

Shares of HTG Molecular Diagnostics (NASDAQ HTGM) traded up $1.74 during mid-day trading on Friday, hitting $4.03. 12,288,601 shares of the stock traded hands, compared to its average volume of 4,496,367. The stock has a market cap of $46.14 and a price-to-earnings ratio of -1.58. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25.

TRADEMARK VIOLATION NOTICE: “Zacks: HTG Molecular Diagnostics Inc (HTGM) Receives Average Recommendation of “Strong Buy” from Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/zacks-htg-molecular-diagnostics-inc-htgm-receives-average-recommendation-of-strong-buy-from-brokerages.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.